RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in 2024
AFFINITY DUCHENNE™ Phase I/II trial of RGX-202 remains on track for dosing in the first half of 2023
Announced intention to file a BLA in 2024 using the accelerated approval pathway for RGX-121 for the treatment of MPS II; pivotal program is active and enrolling patients
$682 million in cash, cash equivalents and marketable securities of as of June 30, 2022; operational runway into 2025
Conference call Wednesday, August 3rd at 4:30 p.m. ET
Conference Call
In connection with this announcement, REGENXBIO will host a conference call and webcast today at 4:30 p.m. ET. A live audio webcast will be available at regenxbio.com/investors. Interested parties may also pre-register for the earnings conference call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Those who plan on participating are advised to dial in 15 minutes prior to the start time.
https://finance.yahoo.com/news/regenxbio-reports-second-quarter-2022-200500994.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.